

## Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum

**Paris, France, Cambridge (Massachusetts, United States), January 12<sup>th</sup>, 2026 – 09:00 a.m. CET**

– Biophytis SA ("the Company"), a pioneering company in the development of transformative therapies impacting longevity, today announces its participation in two leading healthcare and investment events in January 2026:

- The **44th edition of the JP Morgan Healthcare Conference**, to be held from **January 12 to 15, 2026, in San Francisco**. This flagship event is the world's largest healthcare investment forum, bringing together leading players from the pharmaceutical, biotechnology and medical technology industries, as well as the global investment community.
- Biophytis will also participate in the **Biomed Forum**, organized by **All Invest Securities**, which will take place on **January 29, 2026, in Paris**. This annual reference event brings together biotech and medtech companies with French and European institutional investors specialized in the healthcare sector.

These two events will provide Biophytis with complementary opportunities to engage with the financial and pharmaceutical communities, both at an international level in San Francisco and at a French and European level in Paris.

On these occasions, Biophytis will present an update on its latest operational and clinical progress, as well as its development outlook for 2026.

### About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depository Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit [www.biophytis.com](http://www.biophytis.com).

### Biophytis Contacts

#### **Investor Relations**

[investors@biophytis.com](mailto:investors@biophytis.com)

#### **Media Contacts**

Antoine Denry : [antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27

Nizar Berrada : [nizar.berrada@taddeo.fr](mailto:nizar.berrada@taddeo.fr) – +33 6 38 31 90 50